A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury*
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
RATIONALE: Despite recent advances in critical care and ventilator management, acute lung injury and acute respiratory distress syndrome continue to cause significant morbidity and mortality. Granulocyte-macrophage colony stimulating factor may be beneficial for patients with acute respiratory distress syndrome. OBJECTIVES: To determine whether intravenous infusion of granulocyte-macrophage colony stimulating factor would improve clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome. DESIGN: A randomized, double-blind, placebo-controlled clinical trial of human recombinant granulocyte-macrophage colony stimulating factor vs. placebo. The primary outcome was days alive and breathing without mechanical ventilatory support within the first 28 days after randomization. Secondary outcomes included mortality and organ failure-free days. SETTING: Medical and surgical intensive care units at three academic medical centers. PATIENTS: One hundred thirty individuals with acute lung injury of at least 3 days duration were enrolled, out of a planned cohort of 200 subjects. INTERVENTIONS: Patients were randomized to receive human recombinant granulocyte-macrophage colony stimulating factor (64 subjects, 250 μg/M) or placebo (66 subjects) by intravenous infusion daily for 14 days. Patients received mechanical ventilation using a lung-protective protocol. MEASUREMENTS AND MAIN RESULTS: There was no difference in ventilator-free days between groups (10.7 ± 10.3 days placebo vs. 10.8 ± 10.5 days granulocyte-macrophage colony stimulating factor, p = .82). Differences in 28-day mortality (23% in placebo vs. 17% in patients receiving granulocyte-macrophage colony stimulating factor (p = .31) and organ failure-free days (12.8 ± 11.3 days placebo vs. 15.7 ± 11.9 days granulocyte-macrophage colony stimulating factor, p = .16) were not statistically significant. There were similar numbers of serious adverse events in each group. CONCLUSIONS: In a randomized phase II trial, granulocyte-macrophage colony stimulating factor treatment did not increase the number of ventilator-free days in patients with acute lung injury/acute respiratory distress syndrome. A larger trial would be required to determine whether treatment with granulocyte-macrophage colony stimulating factor might alter important clinical outcomes, such as mortality or multiorgan failure. (ClinicalTrials.gov number, NCT00201409 [ClinicalTrials.gov]).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421801 · Cited by 12,941
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
The Acute Respiratory Distress Syndrome
Ware, L. B., & Matthay, M. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005043421806 · Cited by 4,666
Incidence and Outcomes of Acute Lung Injury
Rubenfeld, G. D., Caldwell, E., Peabody, E., Weaver, J., Martin, D. P., Neff, M., Stern, E. J., & Hudson, L. D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050333 · Cited by 3,684
Comparison of Two Fluid-Management Strategies in Acute Lung Injury
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062200 · Cited by 3,538
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa032193 · Cited by 2,565 · cited 2×
“Failure of extrapulmonary organ systems was defined as in recent ARDS Network studies (5, 6, 18).”
BackgroundResultNémeth, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364 · cited 1×
“Potential mechanisms by which GM-CSF might limit the risk or duration of multiorgan failure include reversal of sepsis-induced immunoparalysis and leukocyte deactivation (22), stimulation of pulmonary innate immune function to limit ventilatorassociated pneumonia (15, 23), or mobilization of tissue progenitor cells, i…”
BackgroundGM-CSF Regulates Bleomycin-Induced Pulmonary Fibrosis Via a Prostaglandin-Dependent Mechanism
Moore, B. B., Coffey, M. J., Christensen, P., Sitterding, S., Ngan, R., Wilke, C. A., McDonald, R., Phare, S. M., Peters-Golden, M., Paine, R., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.4032 · Cited by 158 · cited 1×
“Recombinant GM-CSF is particularly appealing as a therapy for patients with ALI/ARDS because preclinical data suggest it may exert beneficial effects through several different mechanisms, including direct protective effects for alveolar epithelial cells (12), effects limiting progression from lung injury to fibrosis (…”
BackgroundSelf-citation
Cited by
The acute respiratory distress syndrome
Matthay, M. A., Ware, L. B., & Zimmerman, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60331 · Cited by 1,706
The immune system’s role in sepsis progression, resolution, and long-term outcome
Delano, M. J., & Ward, P. A. (2016) · Immunological Reviews · doi:10.1111/imr.12499 · Cited by 880
Dickson, R. P., Singer, B. H., Newstead, M. W., Falkowski, N. R., Erb-Downward, J. R., Standiford, T. J., & Huffnagle, G. B. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.113 · Cited by 724
Self-citationSepsis-induced immune dysfunction: can immune therapies reduce mortality?
Delano, M. J., & Ward, P. A. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82224 · Cited by 644
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
Metadata
- Authors
- Paine, R., Standiford, T. J., Dechert, R. E., Moss, M., Martin, G. S., Rosenberg, A. L., Thannickal, V. J., Burnham, E. L., Brown, M. B., & Hyzy, R. C.
- Venue
- Critical Care Medicine
- Published
- 2012-01
- Volume
- 40
- Issue
- 1
- Pages
- 90-97
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W1995791267
- Cited by
- 156
- References
- 8
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.